News

Retinal and choroidal changes were observed in study.

Concise insight on education and training strategies that will optimize use of the port delivery system in retinal diseases.

Using its proprietary software, the company has been able to create models in a fraction of the time typically needed for fitting one.

AMA President Gerald E. Harmon, MD, said in a statement that President Joe Biden’s pandemic plan will make communities safer amid an evolving pandemic and confirmed cases of the Omicron variant.

According to the company, the board will support the advancement of late-stage ophthalmic assets Nyxol and APX3330.

The company’s re:Vive technology features 6 vision diagnostic exams, supported by 5 reimbursable CPT codes in 1 wearable solution.

Some studies have reported that retinal vascular permeability results in choroidal thickening, while others have reported choroidal thinning or no changes.

Chirag Jhaveri, MD, reviews the trial design and results of the LADDER and ARCHWAY studies, which tested the port delivery system in neovascular AMD.

Expert insight on the history of the port delivery system in neovascular AMD and how it has impacted patient experience and outcomes.

Save the dates for this virtual interactive conference featuring top US ophthalmologists.

Patients can get real-time disease monitoring with self-operated device.

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).

Improvements are seen after gene therapy for Leber congenital amaurosis.

Jay Duker, MD, discusses EYP-1901, EyePoint Pharmaceuticals’ sustained-release anti-VEGF drug for the treatment of wet AMD.

Options facilitate increased durability for patients with retinal degeneration.

According to a team of French investigators, every patient hospitalized with severe COVID-19 cases in their study had retinal and choroidal anomalies on indocyanine green angiography and optical coherence tomography images that were possibly related to the virus.

At AAO 2021, Aerie Pharmaceuticals presented the results of their phase 2b clinical trial of AR-15512, a TRPM8 antagonist, for the treatment of dry eye.

The Children’s Vision Equity Alliance was created to improve access in children’s vision and eye health, working to advance equity in children’s vision and eye health through education, policies and partnerships.

Bausch + Lomb's Yolande Barnard shares an update on the FDA approval of XIPERE for the treatment of macular edema associated with uveitis.

A brief overview of the plethora of findings presented at the 2021 American Academy of Ophthalmology meeting held November 12-15 in New Orleans, LA.

In a poster presented at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Mark Wieland, MD, noted that the Port Delivery System with ranibizumab provides drug delivery over an extended period.

Sunir J. Garg, MD, speaks on the influence of COVID-19 universal face masking on the risk of endophthalmitis following intravitreal anti-VEGF injections.

During a presentation at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Veeral Sheth, MD, presented research that found faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular edema (DME) compared with other retinal treatments.

Speaking at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Ines Lains, MD, PhD, explained that the mechanisms of AMD progression currently remain poorly understood and the tools to predict and halt progression are limited.

VUITY, the first and only approved eye drop to treat age-related blurry near vision, provides opportunities for patients looking for spectacle independence.

Ajay Kuriyan, MD, discusses his poster at AAO, "Fluctuations in central subfield thickness associated with worse visual outcomes in patients with diabetic macular edema in clinical trial setting."